- Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer.
- Coughlin SE, Heald B, Clark DF, Nielsen SM, Hatchell KE, Esplin ED, Katona BW.
- JCO Precis Oncol. 2022 Nov [12];6:e2200517. doi: 10.1200/PO.22.00517.
- PMID: 36370464
- PubMed abstract
- Rare MYC-N11S germline mutation indicative of inherited breast cancer in a multigeneration family.
- Budurlean L, Baker M, Broach J.
- BMJ Case Rep. 2022 Nov 11;15(11):e251336. doi: 10.1136/bcr-2022-251336.
- PMID: 36368728
- PubMed abstract
- Source abstract
- Case report
- Systematic mapping review of guidelines for BRCA1/2 genetic testing globally: investigating geographic and regional disparities in health equity for women and families at risk for hereditary ovarian cancer.
- Hughes BN, Jorgensen KA, Cummings S, Morah D, Krause K, Rauh-Hain JA, Herzog TJ.
- Int J Gynecol Cancer. 2022 Nov 11:ijgc-2022-003913. doi: 10.1136/ijgc-2022-003913. Epub ahead of print.
- PMID: 36368709
- PubMed abstract
- Source abstract
- Review
- Inherited Cancer Susceptibility Gene Sequence Variations Among Patients With Appendix Cancer.
- Holowatyj AN, Washington MK, Tavtigian SV, Eng C, Horton C.
- JAMA Oncol. 2022 Nov 11. doi: 10.1001/jamaoncol.2022.5425. Epub ahead of print.
- PMID: 36368039
- PubMed abstract
- Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate Cancer.
- Hollasch M, Antonarakis ES.
- OncLive. 2022 Nov 11.
- Review
- Free Full Text
- Prostate Cancer Has High Rate of Actionable Mutations, Underscoring Need for Testing.
- Rosa K, Antonarakis ES.
- OncLive. 2022 Nov 11.
- Review
- Free Full Text
- Dr. Antonarakis on Therapeutic Agents for Select Patients With mCRPC.
- Antonarakis ES.
- OncLive. OncLive TV. 2022 Nov 11.
- Video
- Free video
- Dr. Shore on the Importance of Genetic Testing in Prostate Cancer.
- Shore N.
- OncLive. OncLive TV. 2022 Nov 11.
- Video
- Free video
- Canonical and uncanonical pathogenic germline variants in colorectal cancer patients by next-generation sequencing in a European referral center.
- Poliani L, Greco L, Barile M, Buono AD, Bianchi P, Basso G, Giatti V, Genuardi M, Malesci A, Laghi L; Alliance Against Cancer.
- ESMO Open. 2022 Nov 7;7(6):100607. doi: 10.1016/j.esmoop.2022.100607. Epub ahead of print.
- PMID: 36356413
- PubMed abstract
- Use of Breast Cancer Risk Factors to Identify Risk-Adapted Starting Age of Screening in China.
- Zheng Y, Dong X, Li J, Qin C, Xu Y, Wang F, Cao W, Xia C, Yu Y, Zhao L, Wu Z, Luo Z, Chen W, Li N, He J.
- JAMA Netw Open. 2022 Nov 1;5(11):e2241441. doi: 10.1001/jamanetworkopen.2022.41441.
- PMID: 36355372
- PubMed abstract
•• Commentary:
Risk-Based Approaches to Breast Cancer Screening in China.
- PMID: 36355377
- PubMed abstract
- Free Full Text